The CFO of Repligen is Exercising Options

By Carrie Williams

Yesterday it was reported that the CFO of Repligen (RGENResearch Report), Jon Snodgres, exercised options to buy 3,957 RGEN shares at $25.26 a share, for a total transaction value of $99.98K.

Following Jon Snodgres’ last RGEN Buy transaction on March 05, 2019, the stock climbed by 32.2%. This recent transaction increases Jon Snodgres’ holding in the company by 15.06% to a total of $2.91 million.

See today’s analyst top recommended stocks >>

Based on Repligen’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $69.45 million and quarterly net profit of $1.66 million. In comparison, last year the company earned revenue of $49.53 million and had a net profit of $4.79 million. The company has a one-year high of $99.25 and a one-year low of $48.26. Currently, Repligen has an average volume of 492.39K.

Starting in July 2019, RGEN received 8 Buy ratings in a row. Three different firms, including Leerink Partners and Stifel Nicolaus, currently also have a Buy rating on the stock.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins).